Why This Biotech Shakeup Didn't Stir Investors


Recently, one of the biggest biotech dividend stocks, PDL BioPharma (NAS: PDLI) , announced that its CFO has left the company for "personal reasons." While investors are always wary of management shakeups, this move had little effect on the company's share price.

In the following video, health-care analysts Max Macaluso and Brenton Flynn discuss this move and one issue PDL BioPharma investors must continue to keep a close eye on.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Why This Biotech Shakeup Didn't Stir Investors originally appeared on Fool.com.

Brenton Flynn and Max Macaluso, Ph.D., have no positions in the stocks mentioned above. The Motley Fool owns shares of PDL BioPharma. Motley Fool newsletter services recommend Biogen Idec, Elan, and PDL BioPharma. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published